GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (NAS:AVDL) » Definitions » FCF Yield %

Avadel Pharmaceuticals (Avadel Pharmaceuticals) FCF Yield % : -7.97 (As of Apr. 27, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Avadel Pharmaceuticals FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Avadel Pharmaceuticals's Trailing 12-Month Free Cash Flow is $-128.51 Mil, and Market Cap is $1,613.18 Mil. Therefore, Avadel Pharmaceuticals's FCF Yield % for today is -7.97%.

The historical rank and industry rank for Avadel Pharmaceuticals's FCF Yield % or its related term are showing as below:

AVDL' s FCF Yield % Range Over the Past 10 Years
Min: -260.54   Med: -9.65   Max: 20.17
Current: -7.97


During the past 13 years, the highest FCF Yield % of Avadel Pharmaceuticals was 20.17%. The lowest was -260.54%. And the median was -9.65%.

AVDL's FCF Yield % is ranked worse than
72.41% of 1080 companies
in the Drug Manufacturers industry
Industry Median: -0.65 vs AVDL: -7.97

Avadel Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was -144.09%.


Avadel Pharmaceuticals FCF Yield % Historical Data

The historical data trend for Avadel Pharmaceuticals's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avadel Pharmaceuticals FCF Yield % Chart

Avadel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.54 -12.52 -16.33 -15.77 -10.13

Avadel Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.65 -20.48 -8.70 -16.61 -8.84

Competitive Comparison of Avadel Pharmaceuticals's FCF Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Avadel Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avadel Pharmaceuticals's FCF Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avadel Pharmaceuticals's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Avadel Pharmaceuticals's FCF Yield % falls into.



Avadel Pharmaceuticals FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Avadel Pharmaceuticals's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-128.511 / 1268.329
=-10.13%

Avadel Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-28.029 * 4 / 1268.329
=-8.84%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avadel Pharmaceuticals FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Avadel Pharmaceuticals FCF Yield % Related Terms

Thank you for viewing the detailed overview of Avadel Pharmaceuticals's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Avadel Pharmaceuticals (Avadel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.
Executives
Thomas S Mchugh officer: Chief Financial Officer 2280 SCHUETZ ROAD, ST. LOUIS MO 63146
Mark Anthony Mccamish director C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Geoffrey Michael Glass director 4721 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Greg J Divis director, officer: Chief Executive Officer 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Richard J Kim officer: Chief Commercial Officer 16 FAIRWAY DRIVE, WEST WINDSOR NJ 08550
Eric J Ende director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Linda Palczuk director 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046
Peter Thornton director TECHNOPATH LIFE SCIENCES PARK, FORT HENRY, BALLINA, CO. TIPPERARY L2 V94 FF1P
Douglas J Williamson officer: Chief Medical Officer AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN L2 D02 T390
Sandra L Hatten officer: See Remarks 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Jason Vaughn officer: Sr. VP, Technical Operations 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Jordan Dubow officer: Chief Medical Officer 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Michael F Kanan officer: See Remarks 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
David P Gusky officer: See Remarks 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Michael S Anderson director, officer: Chief Executive Officer 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15